The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease
https://doi.org/10.14412/2074-2711-2017-1-101-105
Abstract
The review presents the data of recent studies dealing with cognitive impairments (CI) in patients with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features of the pathogenesis and clinical manifestations, as well as current methods for their diagnosis and treatment. Moderate CIs (MCIs) occur in 18.9–55% of patients with PD; the prevalence of dementia during a cross-sectional study approaches 30%. The 2007 Movement Disorder Society criteria and algorithm for the diagnosis of dementia in PD and the 2012 criteria and the algorithm for the diagnosis of MCIs allow one to maximally accurately identify these disorders. Only rivastigmine is now recognized as effective in treating CI in PD and recommended for use. Overall, therapies for CI in PD have been inadequately investigated, making it necessary to conduct further large-scale studies.
About the Authors
G. N. Akhmadeeva
Bashkir State Medical University, Ministry of Health of Russia
Republic Consulting and Diagnostic Center of Extrapyramidal Pathology and Botulinum Toxin Therapy, OOO «Medstandart» National Medical Holding
Russian Federation
Russian Federation
Department of Neurology with Courses of Neurosurgery and Medical Genetics
3, Lenin St., Ufa 450000
133/1, Komsomolskaya St., 450075
R. V. Magzhanov
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology with Courses of Neurosurgery and Medical Genetics
3, Lenin St., Ufa 450000
G. N. Tayupova
Bashkir State Medical University, Ministry of Health of Russia
Republic Consulting and Diagnostic Center of Extrapyramidal Pathology and Botulinum Toxin Therapy, OOO «Medstandart» National Medical Holding
Russian Federation
Russian Federation
Department of Neurology with Courses of Neurosurgery and Medical Genetics
3, Lenin St., Ufa 450000
133/1, Komsomolskaya St., 450075
A. R. Baitimerov
Republic Consulting and Diagnostic Center of Extrapyramidal Pathology and Botulinum Toxin Therapy, OOO «Medstandart» National Medical Holding
Russian Federation
133/1, Komsomolskaya St., 450075
Russian Federation
133/1, Komsomolskaya St., 450075
References
1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. Epub 2006 Nov 2.
2. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013 Sep;62:132-44. doi: 10.1016/j.freeradbiomed.2013.01.018. Epub 2013 Feb 4.
3. Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol. 2012 Dec;259(12):2621-31. doi: 10.1007/s00415-012-6557-8. Epub 2012 Jun 19.
4. Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010 Aug 15;25(11):1646-51. doi: 10.1002/mds.23135.
5. Chaudhuri KR, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013;8(2):e57221. doi: 10.1371/journal.pone.0057221. Epub 2013 Feb 27.
6. Lawson RA, Yarnall AJ, Duncan GW, et al. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism Relat Disord. 2014 Oct;20(10): 1071-5. doi: 10.1016/j.parkreldis.2014.07.004. Epub 2014 Jul 18.
7. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956.
8. Emre M. Treatment of dementia associated with Parkinson's disease. Parkinsonism Relat Disord. 2007;13 Suppl 3:S457-61. doi: 10.1016/S1353-8020(08)70049-X.
9. Grover S, Somaiya M, Kumar S, Avasthi A Psychiatric aspects of Parkinson's disease. J Neurosci Rural Pract. 2015 Jan;6(1):65-76. doi: 10.4103/0976-3147.143197.
10. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010 Sep 21;75(12):1062-9.doi: 10.1212/WNL.0b013e3181f39d0e.
11. Дамулин ИВ. Патогенетические и терапевтические аспекты деменции при болезни Паркинсона. Журнал неврологии и психиатрии им. C.C. Корсакова. 2009;109(2):73-7. [Damulin IV. Pathogenetic and therapeutic aspects of dementia in Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2009;109(2):73-7. 2009;109(2):73-7. (In Russ.)].
12. Bohnen NI, Mü ller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain. 2010 Jun;133(Pt 6): 1747- 54. doi: 10.1093/brain/awq079. Epub 2010 Apr 22.
13. Compta Y, Ezquerra M, Munoz E, et al. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. Neurosci Lett. 2011 Jan 7;487(2):169-73. doi: 10.1016/j.neulet.2010.10.015. Epub 2010 Oct 15.
14. Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev. 2002 Nov;26(7):785-93.
15. Zweig RM, Cardillo JE, Cohen M, et al. The locus ceruleus and dementia in Parkinson's disease. Neurology. 1993 May;43(5):986-91.
16. Lee JE, Park HJ, Song SK, et al. Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. Neurology. 2010 Nov 30;75(22):2009-16. doi: 10.1212/WNL.0b013e3181ff96bf.
17. Apostolova LG, Beyer M, Green AE, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord. 2010 Apr 30;25(6):687-95. doi: 10.1002/mds.22799.
18. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol. 1992 Dec;49(12):1262-8.
19. Нодель МР, Яхно НН. Нервно-психические нарушения болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2009;(2):3–8. [Nodel' MR, Yakhno NN. Nervous and mental disorders of parkinson's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;(2):3-8. (In Russ.)]. doi: http://dx.doi.org/10.14412/2074-2711-2009-30.
20. Яблонская АЮ. Влияние вегетативных расстройств на качество жизни больных болезнью Паркинсона. Автореф. дисс. канд. мед. наук. Москва; 2011. 24 с. [Yablonskaya AYu. The influence of vegetative disorders on the quality of life of patients with Parkinson's disease. Autoref. diss. cand. med. sci. Moscow; 2011. 24 p.]
21. Хидиятова ИМ, Ахмадеева ГН, Гилязова ИР и др. Исследование влияния полиморфизма гена СОМТ на характер клинического течения болезни Паркинсона. Неврологический журнал. 2013;(3):22-7. [Khidiyatova IM, Akhmadeeva GN, Gilyazova IR, et al. A study of the influence of COMT gene polymorphism on the nature of the clinical course of Parkinson's disease. Nevrologicheskii zhurnal. 2013;(3):22-7. (In Russ.)].
22. Williams-Gray CH, Hampshire A, Barker RA, et al. Attentional control in Parkinson's disease is dependent on COMT Val158Met genotype. Brain. 2008 Feb;131(Pt 2):397-408. doi: 10.1093/brain/awm313. Epub 2008 Jan 4.
23. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009 Nov;132(Pt 11):2958-69. doi: 10.1093/brain/awp245. Epub 2009 Oct 7.
24. Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol. 2005 Jul;252(7):833-8. Epub 2005 Mar 21.
25. Guerini FR, Beghi E, Riboldazzi G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol. 2009 Nov;16(11):1240-5. doi: 10.1111/j.1468-1331.2009.02706.x. Epub 2009 Jun 15.
26. Alves G, Brоnnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.
27. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21; 75(12):1055-61. doi: 10.1212/WNL.0b013e3181f39a78. Epub 2010 Aug 18.
28. Otto M, Esselmann H, Schulz-Shaeffer W, et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease. Neurology. 2000 Mar 14; 54(5):1099-102.
29. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 2003 Feb;18(2):186-90.
30. Noguchi M, Yoshita M, Matsumoto Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005 Oct 15;237(1-2):61-5.
31. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014 Apr 15;29(5):634-50. doi: 10.1002/mds.25857.
32. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010 Aug;120(2):131-43. doi: 10.1007/s00401-010-0711-0. Epub 2010 Jun 20.
33. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel- based morphometry. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):254-9. Epub 2006 Oct 6.
34. Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage. 2007 Jan 15;34(2):714-23. Epub 2006 Nov 17.
35. Левин ОС. Психические расстройства при болезни Паркинсона и их коррекция. В кн.: Экстрапирамидные расстройства. Руководство по диагностике и лечению. Москва: Медпресс-информ; 2002. C. 125-51. [Levin OS. Mental disorders in Parkinson's disease and their correction. In: Ekstrapiramidnye rasstroistva. Rukovodstvo po diagnostike i lecheniyu [Extrapyramidal disorders. A guide to diagnosis and treatment]. Moscow: Medpress-inform; 2002. P. 125-51.]
36. Захаров ВВ, Вахнина НВ. Когнитивные нарушения при нейродегенеративных заболеваниях. Медицинский совет. 2013;(4):30-5. [Zakharov VV, Vakhnina NV. Cognitive disorders in neurodegenerative diseases. Meditsinskii sovet. 2013;(4):30-5. (In Russ.)].
37. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988 Jan;1(1):24-36.
38. Литвиненко ИВ, Одинак ММ, Шатова АВ, Сологуб ОС. Структура когнитивных нарушений при разных стадиях болезни Паркинсона. Вестник Российской Военно-медицинской академии. 2007;(3):21-9. [Litvinenko IV, Odinak MM, Shatova AV, Sologub OS. The structure of cognitive impairment at different stages of Parkinson's disease. Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2007;(3):21-9. (In Russ.)].
39. Левин ОС, Батукаева ЛА, Смоленцева ИГ. Диагностика и лечение деменции при болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2008;108(6):91-7. [Levin OS, Batukaeva LA, Smolentseva IG. Diagnosis and treatment of dementia in Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(6):91-7. (In Russ.).]
40. Grossman M, Carvell S, Gollomp S, et al. Sentence comprehension and praxis deficits in Parkinson's disease. Neurology. 1991 Oct; 41(10):1620-6.
41. Jacobs DM, Marder K, Cоtе LJ, et al. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology. 1995 Sep;45(9):1691-6.
42. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007 Jul;130(Pt 7):1787-98. Epub 2007 May 29.
43. Kaul S, Elble RJ. Impaired pentagon drawing is an early predictor of cognitive decline in Parkinson's disease. Mov Disord. 2014 Mar;29(3): 427-8. doi: 10.1002/mds.25807. Epub 2014 Jan 21.
44. Biundo R, Weis L, Facchini S, et al. Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord. 2014 Apr;20(4):394-9. doi: 10.1016/j.parkreldis.2014.01.009. Epub 2014 Jan 22.
45. Крыжановский ГН, Карабань ИН, Магаева СВ и др. Болезнь Паркинсона (Этиология, патогенез, клиника, диагностика, лечение, профилактика). Москва: Медицина; 2002. 335 c. [Kryzhanovskii GN, Karaban' IN, Magaeva SV, et al. Bolezn' Parkinsona (Etiologiya, patogenez, klinika, diagnostika, lechenie, profilaktika) [Parkinson's disease (Etiology, pathogenesis, clinic, diagnostics, treatment, prevention)]. Moscow: Meditsina; 2002. 335 p.]
46. Артемьев ДВ, Глозман ЖМ. Нарушения высших психических функций при болезни Паркинсона. Достижения в нейрогериатрии. 1995;(1):46-58. [Artem'ev DV, Glozman ZhM. Violations of higher mental functions in Parkinson's disease. Dostizheniya v neirogeriatrii. 1995;(1):46-58. (In Russ.)].
47. Levin BE, Tomer R, Rey GJ. Cognitive impairments in Parkinson's disease. Neurol Clin. 1992 May;10(2):471-85.
48. Ахмадеева ГН, Таюпова ГН, Байтимеров АР и др. Факторы риска возникновения когнитивных нарушений и расстройств ночного сна у пациентов с болезнью Паркинсона. Казанский неврологический вестник им. Бехтерева. 2015;(3):5-10. [Akhmadeeva GN, Tayupova GN, Baitimerov AR, et al Risk factors for cognitive impairment and disorders of night sleep in patients with Parkinson's disease. Kazanskii nevrologicheskii vestnik im. Bekhtereva. 2015;(3):5-10. (In Russ.)].
49. Стёпкина ДА, Захаров ВВ, Яхно НН. Когнитивные нарушения при прогрессировании болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008; (10):13-9. [Stepkina DA, Zakharov VV, Yakhno NN. Cognitive impairments in the progression of Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(10):13-9. (In Russ.)].
50. Ganga G, Alty JE, Clissold BG, et al. Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase. Mov Disord. 2013 Apr;28(4):476-81. doi: 10.1002/mds.25335. Epub 2013 Feb 6.
51. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community- based, prospective study. Neurology. 2001 Mar 27;56(6):730-6.
52. Kim EJ, Baek JH, Shin DJ, et al. Correlation of sleep disturbance and cognitive impairment in patients with Parkinson's disease. J Mov Disord. 2014 Apr;7(1):13-8. doi: 10.14802/jmd.14003. Epub 2014 Apr 30.
53. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003 Apr;2(4):229-37.
54. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec;22(16):2314-24.
55. Litvan I, Goldman JG, Trö ster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012 Mar;27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24.
56. Geurtsen GJ, Hoogland J, Goldman JG, et al; MDS Study Group on the Validation of PD- MCI Criteria. Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis. 2014;4(2): 131-7. doi: 10.3233/JPD-130304.
57. Нодель МР, Яхно НН. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(5):32-8. [Nodel' MR, Yakhno NN. Mirapex (pramipexole) in the treatment of nonmotor disorders in Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2008;108(5):32-8. (In Russ.)].
58. Inzellberg R, Bonuccelli U, Schechtman E. Association between amantadine and onset of dementia in Parkinson disease. Mov Disord. 2006 Sep;21(9):1375-9.
59. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo- controlled, multicenter study. Mov Disord. 2011 Aug 15;26(10):1851-8. doi: 10.1002/mds.23738. Epub 2011 Apr 15.
60. Dobkin RD, Trö ster AI, Rubino JT, et al. Neuropsychological Outcomes Following Psychosocial Intervention for Depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2014 Winter;26(1):57-63. doi: 10.1176/appi.neuropsych.12120381.
61. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3): CD006504. doi: 10.1002/14651858.CD006504.pub2.
62. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct;26 Suppl 3:S42-80. doi: 10.1002/mds.23884.
63. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9.
64. Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012 Sep 1;27(10):1230-8. doi: 10.1002/mds.25098. Epub 2012 Aug 22.
65. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double- blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 Jul;8(7):613-8. doi: 10.1016/S1474-4422(09)70146-2. Epub 2009 Jun 10.
66. Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord. 2009 Jun 15;24(8):1217-21. doi: 10.1002/mds.22495.
67. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. doi: 10.1016/S1474-4422(10)70194-0. Epub 2010 Aug 20.
68. Литвиненко ИВ, Одинак ММ, Могильная ВИ и др. Эффективность и безопасность применения галантамина (реминила) в случаях деменции при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(12):21-9. [Litvinenko IV, Odinak MM, Mogil'naya VI, et al. The efficacy and safety of galantamine (reminyl) in cases of dementia in Parkinson's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;110(12):21-9. (In Russ.)].
69. Boggio PS, Ferrucci R, Rigonatti SP, et al. Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease. J Neurol Sci. 2006 Nov 1;249(1):31-8. Epub 2006 Jul 14.
70. Elder GJ, Taylor JP. Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias? Alzheimers Res Ther. 2014 Nov 10;6(9):74. doi: 10.1186/s13195-014-0074-1. eCollection 2014.
71. Ikeguchi M, Touge T, Nishiyama Y, et al. Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson's disease. J Neurol Sci. 2003 May 15;209(1-2):41-6.
72. Sinforiani E, Banchieri L, Zucchella C, et al. Cognitive rehabilitation in Parkinson's disease. Arch Gerontol Geriatr Suppl. 2004;(9):387-91.
73. Sammer G, Reuter I, Hullmann K, et al. Training of executive functions in Parkinson's disease. J Neurol Sci. 2006 Oct 25;248(1-2):115-9. Epub 2006 Jun 12.
74. Nombela C, Bustillo PJ, Castell PF, et al. Cognitive rehabilitation in Parkinson's disease: evidence from neuroimaging. Front Neurol. 2011 Dec 22;2:82. doi: 10.3389/fneur.2011.00082. eCollection 2011.
75. Paris AP, Saleta HG, de la Cruz Crespo Maraver M, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord. 2011 Jun;26(7):1251-8. doi: 10.1002/mds.23688. Epub 2011 Mar 25.
76. Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord. 2013 Jul;28(8):1034-49. doi: 10.1002/mds.25377. Epub 2013 Feb 20.
77. Shulman LM, Taback RL, Bean J, et al. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001 May;16(3):507-10.
Review
For citations:
Akhmadeeva GN, Magzhanov RV, Tayupova GN, Baitimerov AR. The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):101-105. (In Russ.) https://doi.org/10.14412/2074-2711-2017-1-101-105
Views:
774
Email this article 